The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and one IL-17 inhibitor (Novartis’s Cosentyx). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in March 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation. The impending entry of additional IL-17 inhibitors (Eli Lilly’s Taltz, UCB’s bimekizumab, and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapy for this indication (Pfizer’s Jak inhibitor Xeljanz) will also shift market dynamics.

Questions answered:

  • How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
  • What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
  • What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?

Content highlights:

Geographies: United States, EU5, Japan

Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research

Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations

Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2028, segmented by brands/generics and epidemiological subpopulations

Emerging therapies: Phase III/PR: 4 drugs; Phase II: 2 drugs

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Axial Spondyloarthritis | Unmet Need | Detailed, Expanded analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Ci...

View Details

Axial Spondyloarthritis | Landscape & Forecast | Disease Landscape & Forecast

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (

View Details

Axial Spondyloarthritis | Current Treatment | Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and th...

View Details

Axial Spondyloarthritis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key axial spondyloarthriti...

View Details